Aseptic loosening in non-augmentable versus augmentable tibial baseplate total knee arthroplasty designs: a single-centre comparative 10-year outcomes study
The Knee · 2025-12 · 57 · 228-236
DOI: 10.1016/j.knee.2025.08.013 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Knee, 2025-12. Verfasst von Saskia Locke und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Trauma and Orthopaedics, Glasgow Royal Infirmary, Glasgow, UK. Electronic address: saskia.locke@doctors.org.uk. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Knee, Prosthesis Failure, Knee Prosthesis, Prosthesis Design. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Aseptic tibial loosening is a leading cause of revision in total knee arthroplasty (TKA). Previous work has highlighted concerns over the 5-year survivorship of a specific non-augmentable NexGen Legacy Posterior Stabilised (LPS) tibial baseplate. This study compares the long-term outcomes of augmentable versus non-augmentable tibial implants with a minimum 10-year follow-up. METHODS: A retrospective analysis identified patients undergoing primary cemented TKA between 2009 and 2014. Patients were categorised by tibial baseplate type (augmentable vs. non-augmentable). The primary outcome was aseptic loosening, assessed using Kaplan-Meier survival analysis. Secondary outcomes included overall revision rates and reasons for revision with a subgroup analysis by age and BMI. RESULTS: Among 1830 TKAs, revision rates were significantly higher in the non-augmentable group (6.4 % vs. 4.1 %; p = 0.036). Aseptic loosening was five times more common with non-augmentable implants (2.5 % vs. 0.7 %; p = 0.005). Kaplan-Meier analysis showed significantly reduced survivorship in the non-augmentable group due to aseptic loosening (p = 0.0012, HR = 0.262), with a marked decline after 100 months. Patients under 65 with higher BMI had greater risk, with aseptic loosening occurring in 9.1 % of those with BMI > 40 kg/m2. CONCLUSION: Non-augmentable NexGen LPS tibial implants are associated with higher rates of aseptic tibial loosening at long-term follow-up when used in combination with a posterior stabilised NexGen femoral implant. Younger, high-BMI individuals are at particular risk. These findings support the need for further investigation into the mechanisms of implant failure, as well as a more granular approach to data reporting within large-scale registries to avoid camouflage by more successful implants of the same brand.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Trauma and Orthopaedics, Glasgow Royal Infirmary, Glasgow, UK. Electronic address: saskia.locke@doctors.org.uk.
- Department of Trauma and Orthopaedics, Glasgow Royal Infirmary, Glasgow, UK; University of Glasgow, UK.
- University of Glasgow, UK.
- Department of Trauma and Orthopaedics, Glasgow Royal Infirmary, Glasgow, UK.
Zitieren
APA
Locke, S., Doonan, J., Bailey, E., Seymour-Jackson, E., Campbell, N., Blyth, M. J. G., & Jones, B. G. (2025). Aseptic loosening in non-augmentable versus augmentable tibial baseplate total knee arthroplasty designs: a single-centre comparative 10-year outcomes study. The Knee, 57, 228-236. https://doi.org/10.1016/j.knee.2025.08.013
Vancouver
Locke S, Doonan J, Bailey E, Seymour-Jackson E, Campbell N, Blyth MJG, et al. Aseptic loosening in non-augmentable versus augmentable tibial baseplate total knee arthroplasty designs: a single-centre comparative 10-year outcomes study. The Knee. 2025;57:228-236. doi:10.1016/j.knee.2025.08.013
BibTeX
@article{Locke2025,
author = {Locke, Saskia and Doonan, James and Bailey, Emma and Seymour-Jackson, Emily and Campbell, Nathan and Blyth, Mark J G and Jones, Bryn G},
title = {Aseptic loosening in non-augmentable versus augmentable tibial baseplate total knee arthroplasty designs: a single-centre comparative 10-year outcomes study},
journal = {The Knee},
year = {2025},
volume = {57},
pages = {228--236},
doi = {10.1016/j.knee.2025.08.013}
}
EUVIMED